Illumina, Inc. (ILMN) Earnings Call Transcript & Summary
February 6, 2025
Earnings Call Speaker Segments
Salli Schwartz
executiveGood day, everyone, and thank you for joining the earnings call covering the fourth quarter and the full year 2024. On today's call, we'll walk through the financial results that were issued following the market close and share some thoughts regarding our commercial activity, and after that, we'll open things up for a question and answer session. You can locate our earnings release within the investor relations portion of our website, illumina.com. Delivering prepared remarks for Illumina today will be Jacob Thaysen, our Chief Executive Officer, alongside Ankur Dhingra, our Chief Financial Officer. Jacob is going to speak about where Illumina's business currently stands, and Ankur will take everyone through the financial results for Core Illumina. Just a reminder that Grail was divested by us in June of 2024. If you'd like to look at historical financial results for Grail and Consolidated Illumina, those can be found in our earnings release as well as our SEC filings. We're going to talk about non-GAAP results, which factor in stock-based compensation; we'd encourage everyone to look over the GAAP reconciliation of those non-GAAP measures, which is included in today's release and in the supplementary data posted on our website. While we move through the results, keep in mind that year-over-year means comparisons to the equivalent period in fiscal 2023, whereas sequential means compared to the third quarter of fiscal 2024. Also, be aware that every revenue growth rate we discuss is given on a constant currency basis so that the effect of foreign exchange fluctuations is excluded. This call is being recorded, and the audio portion will be archived in the investor section of our website. It is our intent that all forward-looking statements about our financial results and commercial activity made during today's call will be protected under the Private Securities Litigation Reform Act of 1995. Forward-looking statements carry risks and uncertainties. Actual events or results may differ materially from those projected or discussed. All forward-looking statements rest upon information currently available, and Illumina assumes no obligation to update these statements. To better understand the risks and uncertainties that could cause actual results to differ, we refer you to the documents that Illumina files with the Securities and Exchange Commission, including Illumina's most recent Forms 10-Q and 10-K; with that, I will now turn the call over to Jacob.
Jacob Thaysen
executiveThanks, Salli, and good afternoon, everyone. Prior to diving in, I'd like to briefly speak about the announcement that came recently from China's Ministry of Commerce, something we recognize is front and center for a lot of you as well as for us; we're talking with the appropriate parties and moving quickly to obtain more details so we can get this resolved. Illumina has operated in China for many years, and we keep serving those local markets there, covering our clinical as well as research customers. No matter where Illumina does business, we follow every law and regulation that applies. Also, just to remind everyone, roughly 7% of our worldwide revenue comes from China, and we still see a substantial chance to deliver our innovations into that country's healthcare ecosystem. Now I'll move to the broader review. For Illumina, 2024 was a year of transformation, which lets us head into 2025 carrying momentum. As I told you last month, we achieved meaningful strides toward our strategic objectives in spite of the market environment. We rolled out our fresh corporate strategy aimed at getting back to revenue growth in 2025 and reaching high single-digit revenue growth by 2027. We sharpened our attention on customers and partners so the genomics ecosystem could expand further. We brought out new innovations spanning the sequencing workflow to back what our customers care about most, the best possible quality of insight at the lowest end-to-end cost. Our NovaSeq X transition moved ahead strongly, with research and clinical customers increasingly relying on these instruments for sequencing that is deeper and broader. We assembled a new leadership team and fine-tuned our organizational structure, and we introduced strong operational excellence programs to lift our margins and generate double-digit to teens EPS growth. Our transformation has only just begun, and we're confident 2025 will move us nearer to our objectives. Now to our Q4 results: during the fourth quarter, Illumina brought in revenue of $1.1 billion, beating expectations and showing roughly 1% growth versus the prior year. The shift to NovaSeq X keeps going well. Q4's year-over-year revenue growth came mostly from consumables, since customers raised their instrument utilization. During 2024, NovaSeq X pull-through came to an average of $1.3 million per system. On a sequential basis, our results beat expectations thanks to shipments of the NovaSeq X Series that came in higher than anticipated; we placed 91 instruments in the quarter, which lifted the installed base to 630. Looking across our regions, America's revenue, which makes up more than half of our business, rose 3% year-over-year on a constant currency basis. Europe revenue climbed 3%, EMEA revenue fell 10%, and Greater China revenue grew 1%; we stay focused on three key priorities that guide execution: first, deeper collaboration with customers and partners; second, ongoing innovation; and third, a commitment to commercial and operational excellence. Our first priority, deeper customer and partner collaboration, centers on delivering a variety of targeted solutions that address the increasingly diverse needs of our customer base, advance the broader ecosystem, and make higher sequencing volumes possible. In the previous month, we shared multiple instances of teaming up with top companies to expand our footprint where technology, healthcare, and pharma converge. Through these alliances, our clients will be able to produce richer, more granular information and deeper understanding. Our collaboration with NVIDIA, which we unveiled not long ago, combines Illumina's software strengths with NVIDIA's cutting-edge AI resources to improve how multiomics data is analyzed and interpreted for customers. Additionally, we're excited to participate in the Truvera genome project with Truvera, Regeneron, and a number of prominent health systems throughout the US. Jointly, we're building one of the biggest genetic repositories tied to phenotypic information, sequencing 10 million exomes solely with Illumina's technology. Our next focus area is ongoing innovation, which relies on engaging with clients and collaborators to exchange perspectives and back their goals; in December, we started delivering the fresh single flow cell NovaSeq X, offering identical top-tier performance and velocity as the NovaSeq X Plus yet at a more budget-friendly cost; we likewise started shipping our updated 25B, 100, and 200 cycle kits for the NovaSeq X, crucial for pushing forward multiomics uses. These kits further enable our just-launched single-cell option, once called PipSeq, from Confluent Biosciences. As we noted in the strategy update, our clients are progressively zeroing in on obtaining the finest quality insights at the cheapest overall expense. To address this, we keep growing our lineup of completely automated, simplified workflows, such as our new MySeq I 100, which speeds up sample-to-answer oncology, microbiology, and various other uses. Adoption following the Q4 debut has been robust; we positioned over 70 devices with early access clients prior to the close of the year; furthermore, we've been working on a proteomics offering together with Standard BioTools; it's a totally integrated, start-to-finish workflow providing excellent automation and user-friendliness relative to competing available products. As part of this introduction, Illumina revealed a trial proteomics initiative to examine 50,000 UK Biobank specimens, creating a fresh set of NGS-based proteomics information. We're additionally broadening our early access initiative for our Constellation map read technology. Clients who opted to join the initiative have been heartened by Constellation's capacity to spot structural variants that were formerly difficult to pinpoint using short-read sequencing. As we stated in our strategy update the prior year, we're dedicated to informing clients about our innovation plans at sector conferences and gatherings. We anticipate revealing more at the ATBT conference later this month. Another equally vital focus is our dedication to commercial and operational superiority. By drawing nearer to our clients, boosting efficiency, and refining investment outlays, we're establishing a groundwork that fuels Illumina's sustained achievement. We've achieved significant strides in fostering a culture where each staff member adds to commercial and operational superiority; in Q4, we realized extra cost reductions through improved manufacturing and logistics efficiencies, adding over $100 million in savings throughout 2024. The fact that we can still enhance our margins despite challenging market dynamics really demonstrates what the new Illumina operating model is all about. That's something you'll continue to observe moving forward. Now, when we look at 2025, our guidance doesn't try to incorporate any effects from the recent announcements regarding China, which we are evaluating without delay. Our full-year guidance additionally takes into account a consideration of today's macroeconomic and political landscapes. We're keeping a close watch on the changing situation in Washington, especially concerning research funding. At the end of the day, we're dedicated to standing behind our customers around the world and the vital work they perform to push scientific discovery forward through the capabilities of genomics. With all of this in mind, our outlook for 2025 matches what we communicated back in mid-January. We still anticipate revenue growth in the low single-digit percentage range on a constant currency basis, along with a non-GAAP operating margin of roughly 23%, which represents a 170 basis points gain over 2024. Additionally, we expect diluted EPS between $4.50 and $4.65. We possess a distinct vision for growing the thrilling markets where we compete, plus a roadmap that defines the future to assist our customers. Our attention stays fixed on meeting our long-term financial objectives: reaching high single-digit percentage growth by 2027, achieving more than 500 basis points of operating margin expansion, and delivering double-digit to teens EPS growth. As we've mentioned previously, three growth drivers will assist us in reaching these aims: first, leading with our robust core sequencing business as we advance the X transition; second, scaling our move into multiomics during this year and the next; and third, broadening our data and services to introduce an extra layer of growth. Prior to handing things over to Ankur, I'd like to express gratitude to our employees for their dedication and performance over the last year. I take great pride in the Illumina team for remaining focused on bringing innovation to market that supports our customers and the patients they serve, while also driving improvements in margin. I'll now invite Ankur to provide further detail on our 2024 results and what we expect for 2025.
Ankur Dhingra
executiveThanks, Jacob. Good afternoon, everyone. I'll provide an overview of our financial results, add more detail on revenue, expenses, earnings, and balance sheet developments, and then discuss our outlook moving forward. All financial information, including guidance, that we've shared on this call pertains to Core Illumina only and does not include Grail. Every revenue growth rate is expressed on a constant currency basis. In Q4, Illumina's revenue reached $1.1 billion, surpassing our expectations; we achieved meaningful progress toward our objectives of advancing customer-centric innovation, expanding margins, and growing EPS. Cash generation continues to be robust, and we keep deploying cash in line with our capital allocation strategy. Let me offer additional detail, beginning with revenue. During the fourth quarter, we recorded $1.1 billion in revenue, which exceeded what we had projected and marked a 1% gain compared with the same period a year earlier. The main driver of this expansion was our high-throughput consumables segment, and the outperformance relative to our forecast was tied to NovaSeq X placements, including promising uptake from clinical customers. Revenue from sequencing consumables reached $698 million, up approximately 2% from the prior-year period, propelled by the continued migration of high-throughput sequencing onto X together with mid-throughput consumables growth set against an easy year-ago comparison. As Q4 ended, in line with the X transition pace we have previously described, more than 65% of high-throughput gigabases shipped and about 40% of high-throughput consumables revenue originated from the NovaSeq X series. Now for what happened with sequencing. On our connected high- and mid-throughput machines, total sequencing GB produced grew by more than 30% compared with a year earlier, and we saw robust gains across both clinical and research clients. Q4 sequencing instruments revenue came in at $155 million, a 3% drop year over year, mostly because fewer mid-throughput units shipped — our customers are still holding back on capital purchases and managing cash flow — though the successful MySeq I 100 launch partly made up for that. Sequencing service and other revenue reached $151 million, down 1% from a year ago, largely reflecting the timing of some strategic partnership revenue booked last year. As we expected, instrument services contracts, CDX agreements, and our informatic solutions all delivered growth. Turning to the other parts of Illumina's P&L: our non-GAAP gross margin came in at 67.4% during Q4, which mirrors the usual fourth-quarter pattern of having a larger share of instrument sales in the mix. Compared with the same period a year ago, that non-GAAP gross margin figure rose by 270 basis points. The main reasons were our operational excellence programs, which keep boosting productivity and generating cost savings, plus ongoing expansion in consumables. At $526 million, non-GAAP operating expenses show both our efforts to keep costs in check and spending on projects linked to important investments. For Q4, non-GAAP operating margin reached 19.7%, which is 120 basis points higher than a year earlier, showing that our discipline and operational excellence work is paying off. For the quarter, our non-GAAP tax rate was lower, at 23.7%, and for the full year 2024 it was 23.6%. Non-GAAP net income in Q4 totaled $152 million. During the quarter, our non-GAAP weighted average diluted share count stood at roughly 160 million. When you put all of that together, non-GAAP earnings per diluted share came to $0.95, ahead of our expectations, driven by higher revenue and a bit of benefit from a lower tax rate. Now moving to cash flow and balance sheet items for the quarter: cash generated by operations was $364 million. Capital expenditures totaled $42 million, leaving free cash flow of $322 million. During Q4, we bought back 134,000 shares of Illumina stock, spending $17 million, which works out to an average price of $129 per share. We finished the year holding roughly $1.22 billion across cash, cash equivalents, and short-term investments. Jacob walked through the considerable strides we've taken toward the targets we've established for Core Illumina. We have likewise rebuilt a powerful capacity to generate cash along with a sturdy balance sheet, which sets us up nicely going forward. Shifting to our 2025 guidance now, as Jacob noted, we are in the process of evaluating the recent announcement out of China, and none of the impact from that announcement is reflected in our 2025 guidance. A continuation of present macroeconomic and political conditions is another assumption behind our guidance. What we expect overall for fiscal year 2025 stays consistent with what we said a few weeks ago; we anticipate constant currency revenue growth somewhere in the low single-digit percentage range, with more weight in the back half of the year, propelled by the NovaSeq X transition. On a constant currency basis, we anticipate sequencing consumables will rise in the low single digits, fueled by robust sequencing activity, particularly among our clinical customers. Interest from the research community is strong for multiomic product launches such as single-cell and proteomics; additionally, we remain on track for about 75% of high-throughput gigabases shipped to make the switch to the X series by the second half of 2025. Regarding instruments, we are taking the view that our customers will keep watching their capital investments carefully, so we project instrument placements will moderate in 2025, which mirrors a low single-digit decrease in sequencing instrument revenues on a constant currency basis. For your modeling purposes, the customary pull-through assumptions appear in our slides. We anticipate total sequencing revenue growth will match total Illumina revenue growth year-over-year. Turning to the rest of the P&L, we project a core non-GAAP operating margin of about 23%, which is an expansion of 170 basis points compared with 2024. Our operating margin expectations capture the gains from our ongoing gross margin improvement and expense reduction efforts, partly offset by inflation and market-based merit increases; in addition, we are bringing down our non-GAAP tax rate, which is now projected at roughly 22.5%. Tallying it all up, we anticipate non-GAAP diluted earnings per share between $4.50 and $4.65, which represents 10% growth at the midpoint. Our slides also contain other financial information that should assist with modeling purposes. The presentation will be available on our investor relations website after our prepared remarks. Turning now to Q1 of 2025: as I said earlier, our guidance isn't meant to capture any effect from the recent China announcement. For that quarter, we're projecting revenue that's flat to down 1% versus the prior year on a constant currency basis, mostly because of a decrease in sequencing instruments along with the timing of some strategic partnership revenues. For Q1, we're looking at a non-GAAP operating margin of roughly 20.5%, with non-GAAP earnings per share between $0.93 and $0.98. With that, I'll hand the call over to Jacob for his closing remarks.
Jacob Thaysen
executiveAppreciate that, Ankur. The work our team got done in 2024 makes me proud. Now that 2025 is underway, the strategy we've refreshed is producing real momentum for customers across the globe. Breakthrough innovations will keep coming from us — the kind that move the ecosystem ahead and build value for every one of our constituents; we're eager to connect with plenty of you at the conferences and events coming up. Thanks for being on today's call. At this point I'll ask the operator to open up the line so we can take your questions.
Vijay Kumar
analystHi everyone. I appreciate you answering my question. So Jacob and Ankur, I want to start at a high level. You mentioned China, and I realize you aren't building in any assumptions about possible disruption. So first, could you give us an update on whatever information you have at this point, plus what portion of our revenue comes from China, and how do clinical and research margins compare there? Then, Ankur, when I look at the guidance, with Q1 flat to down, does that suggest revenues across the full year will land in that low single-digit range? What exit rate does that imply? Thanks.
Jacob Thaysen
executiveThanks, Vijay. You packed quite a few questions into that one, so let me attempt to cover China broadly. As we said earlier, to begin with, this is obviously quite fresh information. We've only been aware of it for a handful of days. To put it in context, though, China represents a major market that has an aging population. Like numerous other countries, it is putting money into healthcare and making it a priority, and it views sequencing as a crucial element of that effort. So that's what we're observing. Naturally, rival companies likewise regard China as a major market opportunity. And we genuinely think that Illumina, thanks to our leading NGS technology and the innovation pipeline we have, is serving Chinese customers and patients extremely well and will keep doing so. As I said, the recent announcement is only a matter of days old, and we are moving quickly with the appropriate parties to reach a resolution. What I can tell you is that, as you're aware, this business accounts for roughly 7% of our total revenue. Beyond that revenue figure, though, we won't be providing further detail on our China business right now.
Vijay Kumar
analystGot it. And Ankur, perhaps regarding the cadence.
Ankur Dhingra
executiveYes. My view on how the year's cadence shapes up hasn't really shifted from what we discussed a few weeks back. The main driver, as you're aware, is the shift to high-throughput sequencing, which means our revenue growth leans more heavily toward the back half of the year. With the move to X and the change in pricing, we do expect pricing to ease somewhat. That's what pushes greater profitability on the top line into the year's second half. Even so, our emphasis on removing costs and pursuing operational excellence should show up across all 12 months.
Vijay Kumar
analystAlright. Thank you, guys.
Jacob Thaysen
executiveThanks.
Dan Brennan
analystThanks, and congratulations on the quarter. I've got a few questions. First, on volumes — I believe you mentioned volume growth above 30% for Q4, which seems like a change from what was shared last quarter. Could you give us more detail on volume trends and elasticity, and what you're assuming for 2025? Related to that, you showed the pull-through figures on the screen. I'd appreciate some perspective on what's baked into 2025 regarding the shift from NovaSeq to NovaSeq X — what are you observing there? Is it spread evenly across the year? Is there an upward trend? Any perspective you can offer regarding how this shapes 2025 would be great. Thanks.
Jacob Thaysen
executiveSure, Dan. Let me begin by once more framing the situation as we see it—what truly energizes us, and what has become evident throughout 2024, is that the shift toward the X keeps building. As our clients transition to the X, they're leveraging it to boost their output and ramp up their sequencing—not only through bigger assays but also by going deeper. We keep observing that a customer who has adopted the X generates substantially higher volume compared to those who remain on the 6K; so that's encouraging. When we first shared those volume figures, our goal was for everyone to recognize they're just a rough guide. You can't treat them as an exact way to tell if the number is 30% or 40%. What really matters is that a lot of volume exists, and the growth we're seeing keeps outpacing the typical rate. Looking further ahead, our expectation is for volume growth to land somewhere near the mid-20% range. Right now we remain above that level, and that should stay true for some time yet. I remain quite happy with the results we've posted, and as Ankur has also mentioned, they demonstrate genuinely solid movement toward the X. We continue to expect that by the middle of the year, over 75% of our volume will be running on the X.
Dan Brennan
analystThat topic has gotten plenty of attention, Jacob. Also, we've released the slide covering every pull-through assumption and so on. As we closed out 2024, pull-through was quite strong across the whole year. We're really happy with how X is ramping now, and we see room for further growth in the coming year too. All the specifics you'd need for modeling appear on that slide.
Puneet Souda
analystYeah. Hello, everyone. I appreciate you fielding my questions. Starting with the first one, Jacob. I'm grateful for what you said earlier regarding the unreliable entity list, though that was a forceful remark coming from China, and clearly you referenced several years and your historically robust standing in China, but might you say a bit more so we can grasp why you believe that will get turned around? Another, bigger software firm was clearly part of this, and it seemed quite targeted; so I just hoped to get clarity on that. Then regarding the clinical transition, Ankur, I was wondering whether you could explain where that 50% gigabyte shipped figure might land in 2025 or once 2025 ends. Thank you.
Jacob Thaysen
executiveYeah. Thank you, Puneet. At the start, as you noted, this is fresh information; we've been aware of it for merely a few days. I don't believe I've said anything about timelines on this at any point when we gain additional insights, or even about whether it's been turned around. I don't think we have, and we won't address that. We're speaking with the pertinent parties, and we'd prefer to keep those conversations confined to the parties until we learn more.
Ankur Dhingra
executiveAlso, naturally, regarding that 50%, I'll add a bit more detail about how the shift to X is going. We've mentioned that by the close of the year, in Q4, no less than two-thirds — or more than 65% — of overall volume has made the move. If you break that down between clinical and research, then for clinical it comes to roughly 50%. In other words, by year-end, half of clinical volume has already switched over to X.
Puneet Souda
analystSo for 2025, when are you expecting that to happen?
Ankur Dhingra
executiveWell, taken as a whole, I'd still say 75%. Looking at the total volume in aggregate, since research is already 80% transitioned, clinical ought to account for the bulk of what's left.
Puneet Souda
analystAll right, I'll rejoin the queue. Thanks.
Doug Schenkel
analystHello there. Good afternoon, everyone. My first topic will be China, and after that I'd like to move to something broader and more long-term. So, to get right down to it, by choosing not to share additional China financial details and by passing up the chance to ring-fence those items, I'm certain you realize this, the result is one more overhang hanging over the stock. So, Ankur, I'd like to know whether you would at minimum be open to discussing the levers that you've pinpointed and that you can use, both at the margin line and through things such as buybacks, to safeguard at least the bottom end of your EPS goals for this year, should you prove unable to turn around the situation in China. That's my first item. Then, on a longer horizon, and somewhat tied to that, Jacob and Ankur, given that you took over a great many issues from the prior leadership group, once you purchase the house, it belongs to you; this company is yours. It feels as though each quarter brings something else. First there's pricing. Then mid-throughput. Now China is the issue, and within a couple of weeks, Roche will give us some fresh announcements. You observe what we observe; actually, you observe more, considering the market opportunity, your network effect, and the fact that you're putting close to a billion dollars into R&D annually. Do you have confidence that you can return to mid-single-digit revenue growth across the coming one to two years and produce better than peer group EPS regardless of circumstances? Are you dedicated to that? Taking it up to that level? Thank you.
Jacob Thaysen
executiveYes. Thank you, Doug; once more there were many questions packed into that; so let me get straight to the heart of it, which is that we, as you're aware, I've held this position for one and a half years, so you can definitely be sure that I regard myself as having complete ownership of the company and of carrying out what must be done in the period ahead. And this summer we introduced a plan saying we would return to high single-digit growth by 2027. In addition, keep delivering double-digit to teens EPS growth and achieve a 26% operating margin; that's our pledge, and that's what we're committing to accomplish; and we'll do the necessary work to reach it.
Ankur Dhingra
executiveYes, and I appreciate it, Jacob. As for the rest of what you asked, we're evaluating every opportunity we can, no matter how things turn out with China. We'll continue pushing forward the things that drive margin expansion, operating margin, and operating leverage. And as we've laid out, there are a number of opportunities in that area. Our base case already assumes 170 basis points of margin expansion compared with a year ago. And we'll continue to drive more margin there. So we're not really stepping away from that, though I do see further opportunities when it comes to earnings growth, and that's something we're strongly focused on right now.
Conor McNamara
analystThank you for that. Appreciate you fellows taking my question. I'm grateful. So regarding the sequencing growth, did the quarter see any effect from, you know, a deceleration compared with Q3 stemming from the greater X placements, or any pullback from, you know, customers who were evaluating the single-cell X and might have dampened consumables growth during the quarter? And you're at 65% conversion already. So it appears to be running ahead of the 75% conversion you mentioned you'd exit Q2 at. So how should we frame the pricing effect early in 2025 if it's going to be lower than what you set out in your list of it? Thanks for the questions.
Jacob Thaysen
executiveYeah. Thank you, Conor. You know, Paul, we remain pleased with the headway we're making on conversion, as you noted, and we're certainly on a solid path toward delivering at mid-year as we've stated, 75%, as you said, versus where we stand today; so we feel good about that. I think also we're still in a spot where volume growth is very high, and, naturally, mix and other factors can affect some of the performance from quarter to quarter, but when we look at trajectory, we're definitely headed the right way. We did expect we'd see a slight deceleration here in Q4. There are fewer working days and other factors that weighed on us. So we had expected some of that. So we feel good about where we stand and that we'll be on the path to deliver. And as you also noted, once we begin to lap the bulk of having the revenue on the X, then, naturally, you'll see additional revenue growth from that. At present we are growing on a different cost basis, so to speak, or price basis, so to speak. So we're encouraged by that, and as a result, we're also anticipating that we'll keep seeing improvement throughout the year in our consumables growth.
Dan Arias
analystHello, everyone. I appreciate you taking the questions. Ankur, could you give us some idea of how far you've gotten through those production and efficiency initiatives you had lined up? In other words, of the opportunity you identified when you arrived at Illumina, how much did you address and realize during 2024, and what remains available to you this year? I'd really like to grasp the untapped potential sitting there for the coming twelve months.
Ankur Dhingra
executiveYes. Absolutely. So 2024 still holds meaningful opportunities. As I see it, what we've achieved includes certain adjustments to how we manufacture, plus some of the easier wins when it comes to streamlining parts of our teams. We've begun this work. The team is already putting it into action. Our capacity to bring together even more of our manufacturing and our R&D operations in Singapore delivers a twofold advantage. Being located in Singapore gives us not just the cost arbitrage — it also lets us generate synergies between the R&D group and the manufacturing group on the ground, which produces both reduced R&D expenses and a cheaper manufacturing operation; beyond that, below the line, it permits me to grow my R&D footprint in Singapore and capitalize on a tax framework that pays off over the long run. A portion of these gains is already showing up in the 2025 guide. On the opex side, we mentioned we've opened an office in India. We discussed it four months ago. We now have 150 people based there, and we've identified a strong pipeline and a substantial structure for continuing to broaden our capabilities in India; additionally, we have multiple initiatives underway across our sales and marketing function and our R&D. Correct. So there are plenty of opportunities across the coming two years, spanning both 2025 and 2026, for continuing to optimize our cost structure here purely on a structural basis.
Rachel Vatnsdal Olson
analystGreat, thanks. So, there have been a handful of inquiries regarding China, and given how early it is, you folks are still working to size up where things stand. Still, could you break down for us at least what the initial thinking was behind the 2025 guidance as it relates to China? You had steered us toward something like a $300 million business in the prior year. So could you share your perspective on whether you anticipated growth or a decline there in 2025? Then my second question concerns Q1. Could you take us through what you're assuming when it comes to consumables growth? Will it rise on a sequential basis in Q1? Or what ought we to expect there? Thanks.
Jacob Thaysen
executiveYes. Appreciate it, Rachel. Let me kick things off on that, and then Ankur can add a bit more color as well; regarding China, like I've said on earlier calls too, our new China head joined us roughly 12 months back, and Jenny along with the team has done a fantastic job sizing up the opportunity there, building additional structure around what we have and a strategy for where our focus will be. She has implemented some organizational changes, and honestly I believe we're beginning to witness that show up in our results as well, which is to say we're starting to see — it's genuinely good to see — growth in China during Q4. And on a sequential basis too, things are beginning to look quite favorable. So as we were guiding, underneath the guide here, our expectation was roughly flat growth for China in 2025.
Ankur Dhingra
executiveCorrect, Jacob. Rachel, I believe we touched on this at our strategy day, and beyond that, over the short term we didn't expect China to add anything substantial in terms of growth. Holding steady would have been a positive. It's really encouraging to see 1% growth in Q4. And of course, given the announcement, we're evaluating the circumstances even as we continue to stand behind our customers there.
Tejas Savant
analystHi there, everyone. Am I coming through clearly?
Jacob Thaysen
executiveYep. That's right, Tejas. All good.
Tejas Savant
analystSo Jacob, on China, I'd like to approach this from a somewhat different angle. I realize you'd prefer not to get into too many particulars here, but this is a significant matter, and we're living in an age of deal-making, aren't we? You know, years ago, plenty of people pushed to keep BGI out of the American market; the company ended up on the military entity list and biosecure, and so forth. Would it be sensible to reverse that, naturally with the right data protections put in place, in return for your company obtaining unrestricted entry to China's market? Things are different now. These days you have other serious rivals apart from BGI. In principle, would you back an effort like that? Then second, regarding the competitive picture, there have been a few notable victories recently for one of the newer players challenging you. One involved the UK Biobank for proteomics, and the other involved Chan Zuckerberg, for single-cell work. Could you give us some insight into what went wrong for you in those cases?
Jacob Thaysen
executiveLet me begin with your first question about China. On that, I'd say first of all that, as I've said previously, we never treat competition lightly; in fact, I welcome it. I think it keeps us sharp. It keeps everyone focused on ensuring customers receive the finest and highest-quality service. Ultimately, rivalry benefits the industry. And we'll go head-to-head with anybody. We're confident our technology leads the field; we keep pushing innovation forward. It makes no difference if it's in America or China. We're confident that our innovations and everything Illumina represents deliver the optimal solutions to our customers. As for what's taking place in Washington, that's for the legislators to sort out. That's a Capitol Hill discussion, and it isn't something over which we hold any sway.
Tejas Savant
analystUnderstood. Then, regarding where things stand with up-and-coming competitors, Jacob, if you don't mind.
Jacob Thaysen
executiveWell, once more, rivals do exist in this space; that's something we acknowledge. My view is that we don't issue announcements to the media for each and every agreement we sign. So that's all I'll say about it.
Tejas Savant
analystUnderstood. That's reasonable. Thanks very much.
Tycho Peterson
analystHi there. Appreciate it. A few items. First, I want to confirm there wasn't any pull forward among the 91 placements during Q4; it doesn't sound like you're flagging that, but I want to verify nothing happened ahead of the new administration and, you know, some anticipated NIH noise. Then regarding clinical momentum for X, I believe you previously said 20% of tests will never transition to X. Does that remain your view? What uptake assumption are you using for 25B? I think it's roughly 50% of customers. And on the pricing side, you know, you've mentioned customer conversations about application-specific pricing, basically, you know, assisting customers in reaching a particular margin target. Where do things stand in that process? And I think you'd need to respond to Tejas's earlier question regarding the UK Biobank. You know, I realize your competitor essentially handed over that business, but, you know, many of these projects exist out there. The UK Biobank was a significant one. How do you compete with a rational competitor in the market? Possibly one that's giving away instruments.
Jacob Thaysen
executiveOkay. Let me begin by addressing the big picture regarding the percentage of customers that will remain. What we aim to capture from a modeling standpoint is simply this: we've observed historically that the vast majority of customers will shift to the X and to the new technology, yet there will always be some portion of customers who, for reasons such as their assay performing well and delivering solid profitability, or because they don't wish to put more money into that area of the business, for instance, remain on, you could say, the older technology for some period. So we've simply noticed that the general rule is roughly 20% will remain, and they will, naturally, shrink more and more as time passes, but transitioning that final portion takes considerably longer than it did for the first, let's say, 75 to 80%. So that's our way of thinking about it. Regarding the UK Biobank, as we also noted in the recent releases, we're currently involved in a 50,000 pilot study on the UK Biobank project. That's the initial step required. That was in fact also where we observed the other protein provider, protein assay provider, actually completed a 50K project prior to pursuing the full one. So we're essentially following the same path and believe we possess a strong solution for that. As you also point out, yes, new competitors exist in the market; ultimately, we're also in a setting where competition exists and everybody must eventually demonstrate they can generate profit; and we have demonstrated that. My view is that demonstrating their capability to do the same falls on our shoulders. If we fail to do so, the bank will ultimately be depleted.
Ankur Dhingra
executiveAlso, could you speak to how pricing works with your clinical clients? There's been talk about pricing tailored to specific applications—basically assisting customers in reaching a margin goal. Yes, that's correct. Let me build on that, Tycho. Regarding pricing tailored to specific applications, we've been in active talks with a good number of our customers and continue those talks for certain emerging tests. With them, we're discussing a distinct pricing structure that supports a far greater volume of sequencing for that test, and collaborating with them to make that a separate line, instead of conversations about lowering prices across the whole portfolio. Some customers have already signed on to this approach and are examining launches of tests across the coming quarters or so, depending on their own clinical timelines, and they'd be included as a highly specific category. So this marks our first venture into working with this group of customers, and so far the early conversations tied to that test have been very encouraging. The next group, during the second and third sets this year that we expect to appear, will involve our proteomics solution along with our single-cell solution. That's where a portion of the initial talks and placements might center on the end-to-end workflow, or on a complete set of studies plus programs, instead of a per GB conversation. So that's also taking shape.
David Westenberg
analystHi. I appreciate you fielding my question. I'll take a somewhat different angle, given what's already been discussed. To start, I'd like to focus on NVIDIA. What exactly do customers gain from this? Could this partnership expand into something larger, and in what way might it affect the network effect involving Illumina and, you know, maintaining engagement through, you know, being familiar with the product? Then I also want to bring up the Truvera deal. I mean, clearly, a few other analysts mentioned the Chan Zuckerberg Biobank, but Truvera stands out since it leans more toward the private sector. Do you believe additional private sector possibilities exist for genome projects? How does the pipeline for genome projects in the private sector appear? And, you know, considering what we might see come from that, how far away are we from perhaps, like, the aspiration of sequencing at birth? Thank you.
Jacob Thaysen
executiveYeah. Thanks, Dave. And, yeah, we are definitely enthusiastic about those relationships or those collaborations as well; and let's begin with the NVIDIA one. With NVIDIA, as every one of us is aware, there is a great deal of capabilities and compute power being deployed by NVIDIA at present for numerous different applications, particularly in AI; and alongside that, we're now entering an area where even today with a sizable cohort of sequencing, but also expanding into multiomics, it demands a great deal of compute power; and although our Dragon platform on FPGA is performing quite well, the customers who have already made investments in GPU infrastructure, you'll want to ensure that the Dragon platform is likewise offered on the GPU platforms; so that is one item that can truly generate, I think, a substantial network effect and genuinely assist our customers in computing an enormous quantity of data. Simultaneously, NVIDIA is also supplying infrastructure for constructing these foundational models that I think will be essential for truly modeling biology going forward and genuinely being crucial for predicting diseases and health for drug discovery and other things. This is demanding a considerable amount of sequencing to build up those sorts of predictive models. And so we are now alongside NVIDIA, we're allowing, we're enabling those models and that programming language on our platforms or our infrastructure so our customers can obtain access to that. So very exciting and certainly a massive network effect beyond genomics, but truly into multiomics as well. Yeah, you're right, Truvera. It's a private sector genome project, and I think we're witnessing a great deal of interest surrounding that just both in the US, but around the world; we're seeing this in the Middle East, UK, Germany, other places. We're seeing that both from sequencing in sovereign countries, but we're also seeing a lot of interest for pharma to get access to much more diverse datasets. There's a great deal happening around that particular item, though broadly, what we're noticing is that pharma is quite keen on collaborating more closely with us across a wide range of applications; these represent a portion of them, and plenty further is on the way regarding this.
Subha Nambi
analystHi, everyone. I appreciate you fielding my question. You've kept research and development spending at a level slightly under $1 billion each year. Does that remain the strategy going forward? In what ways have you reshuffled priorities since assuming leadership of the organization? What metrics should we use to judge whether this spending pays off, given that I understand it's considerably above what competitors spend relative to revenue?
Jacob Thaysen
executiveYes. I appreciate that, Subha. We still hold the view that, on the whole, the chance presented by genomics along with the multiomics chance we're pursuing continues to be substantial and lies ahead of us, and we're only at the beginning of it; and consequently, truly unlocking that market and truly capturing the value of that chance demands ongoing innovation and funding for R&D; so that reasoning holds, yet we're also, and that's the reason we're additionally making a commitment to it, that we will return to a growth trajectory because, clearly, these matters are interconnected. We hold the belief that across the coming 3 years, if we can progress from our current position to, we still possess, and Illumina, I believe, has a reputation for being an extremely, extremely inventive platform. We possess a plan spanning the upcoming 10 years that we think will establish the direction for where genomics and where multiomics will head and genuinely deliver a major effect not just on health but additionally on drug discovery in the future. So that thrills us greatly. That figure is definitely something we keep monitoring. During 2024, we've been collaborating extensively with the R&D group to genuinely address how we can become more productive and streamlined in the way we operate. We've additionally removed expenses in specific areas, and we keep evaluating possibilities. Yet the concept is, naturally, to expand our way toward a different percentage point instead of shrinking our way there.
Sung Ji Nam
analystHello, and thank you for allowing me to ask. This may tie in somewhat with what Dave asked before. Regarding Project Stargate, that $500 billion AI infrastructure effort that got announced — I realize it could still be quite early. But Larry Ellison's remarks about the ambitions, you know, involving personalized cancer vaccines and tumor gene sequencing, made me wonder whether you could speak to what possibilities exist for Illumina to adopt a more proactive stance or part in this effort, and, you know, genuinely assist in shaping that side of the project.
Jacob Thaysen
executiveYes, absolutely. I'd say that's a terrific illustration of what lies ahead. It also really demonstrates how dedicated the US is to advancing healthcare from here and applying new technology toward that. As also came through very clearly in that program, genomics is going to be enormously important within the Stargate project. And I firmly believe Illumina is the obvious partner for it. So the possibilities in front of us are exciting.
Patrick Donnelly
analystHey, everyone. Thanks for fielding the questions. I'd like to dig a bit deeper into the consumables area. Following the pre-announcement, my assumption was that consumables would land somewhere around $20 million above where they actually came in. Could you discuss the outlook for consumables? Could you split that out, consumables versus instruments? And then the final item, I hate to keep hammering away at the China topic, but can you currently make sales into China? I just, I simply want to know how things stand at present. I realize you're navigating the regulatory aspect, but what has the past week looked like? Is selling possible there or not?
Jacob Thaysen
executiveNo. I appreciate that, Patrick. Let me take the last question first. Yes; we keep serving our customers and their patients in China, and we'll do everything we can to keep that going. In our view, the opportunity in China is enormous, and we'll address the present difficulties swiftly and hopefully reach a resolution as quickly as we can. So, Ankur, would you like to address the consumables area?
Ankur Dhingra
executiveOkay, so regarding the consumables piece, Patrick — like we told you when the quarter began, for Q4 consumables we'd said results would come in below Q3 because of how many holidays there were, and what actually happened tracked pretty closely to that path. Moving down from Q3 to Q4 — sorry, from Q4 relative to Q3. Overall, our X came in right about where we expected on the consumables front, so nothing caught us off guard. The rise we saw in research and in clinical, and so on, went in the direction we'd anticipated. 6K came in a touch soft, but when I look at the quarter in total, from where I sit, things landed about where we thought. Nothing struck me as concerning when it comes to trends — whether that's the shift from 6K over to X, or activity levels more broadly. So we're feeling good about the trajectory overall, and about hitting that 75% conversion in the back half of the year.
Patrick Donnelly
analystAnd regarding the Q1 guidance in particular, Ankur, it would help to get the consumables and instruments numbers.
Ankur Dhingra
executiveSure. On the Q1 guidance, I believe I already mentioned that for Q1 I'm steering toward a comparable rise, meaning an increase in sequence from Q4 to Q1 where our consumables are concerned. Our Q1 consumables guidance is likewise up both in sequence and versus the prior year. So as you consider what growth rate to expect for Q1, you should anticipate consumables being up compared with a year earlier, while instruments will probably land on the down side.
Salli Schwartz
executiveWe appreciate everyone being with us. Just a note that you can find a recording of this session in the investor portion of our site. That wraps up today's call, and we hope to connect with you at future conferences and other gatherings.
Operator
operatorOnce more, everyone, that brings us to the end of today's call. We appreciate your joining us. At this point you're free to hang up; and enjoy the rest of your day.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Illumina, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Illumina, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Illumina, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.